tirzepatide gastrointestinal side effects compared to semaglutide Comparative safety and of and tirzepatide: Implications for clinical decision-making in obesity management Gastrointestinal safety of semaglutide and

5.7 Metabolic Acidosis Hyperchloremic, non-anion gap, metabolic acidosis (decreased serum bicarbonate below the normal reference range in the absence of chronic respiratory alkalosis) has been reported in patients treated with QSYMIA [see Adverse Reactions (6.1)]

That is a deliberate position

1000

Assessed the association of genetically proxied GLP-1RAs with T2D and obesity

For the first time, evidence shows that it is possible to retrain the body to resume its own insulin production, potentially freeing millions from the lifelong dependence on daily injections and external insulin therapies

If you are curious where it fits in your plan, that is a great consultation question